Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market Size, Share & Trends Analysis Report By Product | Forecast to 2029
Claim your 20% discount on Global Market Reports with code ONLINE20. Limited time only.
How Will The Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market Valuation Change Between Now And 2029?
The market for glucagon-like peptide (glp)-1 agonists weight loss medication has seen substantial growth in recent years. It’s forecasted to expand from $13.38 billion in 2024 to $15.5 billion in 2025, with a compound annual growth rate (CAGR) of 15.9%. The historically robust growth can be traced back to an increasing occurrence of obesity, a surge in type 2 diabetes cases, heightened awareness of the health risks associated with obesity, increased spending on healthcare, a growing emphasis on managing chronic diseases, and better healthcare accessibility.
The market size for weight loss drugs based on glucagon-like peptide (glp)-1 agonists is anticipated to experience substantial growth in the subsequent years. It’s projected that by 2029, it would have expanded to $28.3 billion, with a compound annual growth rate (CAGR) of 16.3%. Factors contributing to this predicted growth include the rising demand for efficient weight loss methods, the broadening of drug indications beyond diabetes, escalated investment in research and development, the increasing implementation of personalized medicine, and heightening awareness via direct-to-consumer marketing. In the forecast period, major trends include the creation of oral glucagon-like peptide (GLP)-1 compounds, progress in sustained-release drug delivery systems, the integration of digital health tools for tracking, the application of artificial intelligence in drug discovery and creation, and innovative peptide engineering for enhanced effectiveness.
Get A Free Sample Of The Report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=24226&type=smp
What Underlying Factors Are Supporting The Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market Growth?
The glucagon-like peptide (GLP)-1 agonist weight loss drugs market is predicted to experience growth due to the escalating obesity rates. Obesity is a medical condition categorized by an unhealthy amount of body fat that can pose a health risk. The increasing consumption of fast food and sugary beverages, coupled with a lack of proper nutrition, is contributing to the growing obesity rates. As the number of persons battling obesity and its associated health problems increases, so does the need for effective therapies. This demand is leading to an upsurge in the use of glucagon-like peptide (GLP-1) agonist weight loss drugs, which have demonstrated their effectiveness in promoting weight loss and improving metabolic health. Based on data provided by the World Health Organization, a Switzerland-based intergovernmental agency, in March 2024, it was found that in 2022, one out of every eight individuals worldwide suffered from obesity. Of the 2.5 billion adults who were overweight, about 890 million were designated as obese. Overall, 43% of the global adult population was overweight, and 16% were identified as obese. Consequently, the increasing incidence of obesity is fueling the expansion of the glucagon-like peptide (GLP)-1 agonist weight loss drugs market.
Which Sub-Segments Are Driving Growth Within The Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market?
The glucagon-like peptide (glp)-1 agonists weight loss drugsmarket covered in this report is segmented –
1) By Drugs: Semaglutide; Liraglutide; Tirzepatide; Other Drugs
2) By Route of Administration: Parenteral; Oral
3) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Other Pharmacies
Subsegments:
1) By Semaglutide: Ozempic; Wegovy; Rybelsus
2) By Liraglutide: Saxenda; Victoza
3) By Tirzepatide: Mounjaro; Zepbound
4) By Other Drugs: Exenatide; Dulaglutide; Albiglutide; Efpeglenatide
What Future-Focused Trends Are Anticipated In The Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market?
Leading organizations in the glucagon-like peptide (GLP)-1 agonist weight loss drug market are creating innovative therapies for the treatment of obesity to improve efficacy and patient results. These new treatment solutions are therapies designed to simulate the GLP-1 hormone which helps regulate appetite, increase the feeling of fullness, and encourage weight loss. These medications aid in managing obesity through improving metabolic function and maintaining long-term weight control. For instance, in November 2023, the U.S. based pharmaceutical firm, Eli Lilly and Company, gained approval from the U.S. Food and Drug Administration for its Zepbound drug, which is intended for chronic weight management in obese or overweight adults with associated health conditions, such as type 2 diabetes or sleep apnea. The function of this medication is to activate the G-protein-coupled receptors to control appetite and enhance metabolic functionality.
Which Companies Hold A Competitive Edge In The 1691 Market?
Major companies operating in the glucagon-like peptide (GLP)-1 agonists weight loss drugs market are Pfizer Inc., Roche Holding AG, Merck & Co. Inc, Amgen Inc., Eli Lilly and Company, Novo Nordisk A/S, Teva Pharmaceutical Industries Ltd, Boehringer Ingelheim, Jiangsu Hengrui Medicine Co. Ltd, BioAge Labs, Hanmi Pharmaceutical, Innovent Biologics Inc., Viking Therapeutics Inc., Structure Therapeutics Inc., Zealand Pharma A/S, Regor Therapeutics Inc., I-Mab Biopharma (Shanghai) Co. Ltd., Altimmune Inc., TheracosBio LLC., Oramed Pharmaceuticals.
Access The Complete Report Here:
Which Region Dominates The Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market Today?
North America was the largest region in the glucagon-like peptide (GLP) -1 agonists weight loss drugs market in 2024. The regions covered in the glucagon-like peptide (GLP)-1 agonists weight loss drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Customize Your Report Here:
https://www.thebusinessresearchcompany.com/customise?id=24226&type=smp
Browse Through More Reports Similar to the Global Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market 2025, By The Business Research Company
Pharmaceutical Drugs Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/pharmaceutical-drugs-global-market-report
Oral Biologics And Biosimilar Drug Global Market Report 2025
Anti Asthmatics And Copd Drugs Global Market Report 2025
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
